Oncology Nurse Advisor Editorial Board

Ann J. Brady, RN, BSN
Cancer Center
Huntington Hospital
Pasadena, CA
(Communication Challenges)

Jia Conway, DNP, FNP-BC, NP-C
Cancer Care Associates of York
York, PA

Seth Eisenberg, RN, OCN
Seattle Cancer Care Alliance
Seattle, WA

Michele M. Farrington, BSN, RN
University of Iowa Hospitals and Clinics
Iowa City, IA

Donald R. Fleming, MD
Cancer Care Center
Davis Memorial Hospital
Elkins, WV

Arati Jairam-Thodla, MSN, CNP
Gynecologic Oncology
Prentice Women's Hospital
Northwestern Memorial
Chicago, IL

Karen MacDonald, RN, BSN, CPON
Pediatric hematology/oncology
William Beaumont Hospital
Royal Oak, MI

Marlene McGuire, RN, MA, ANP-C

The Bridge Program: Transitions for Adult Cancer Survivors
Center for Cancer Survivorship
The Cancer Institute of New Jersey
New Brunswick, NJ

Kerstin L. McSteen, BSN, MSN, ACHPN, CNS-BC
Pallative Care Service
Abbott Northwestern Hospital
Minneapolis, MN

Maribel Pereiras, PharmD, BCPS, BCOP
Hackensack University Medical Center
Hackensack, NJ
(Stat Consult)

Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC
Fox Chase Cancer Center
Philadelphia, PA

Leah A. Scaramuzzo, MSN, RN-BC, AOCN
The Cancer Institute of New Jersey
New Brunswick, NJ
(For Your Patient)

Debra P. Shelton, EdD, APRN-CS, NE-BC, OCN, CNE
Northwestern State University of Louisiana College of Nursing
Shreveport, LA

Lisa A. Thompson, PharmD
University of Colorado Denver School of Pharmacy
Aurora, CO
(Ask a Pharmacist)

Rosemarie A. Tucci, RN, MSN
Lankenau Hospital
Wynnewood, PA

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions